N/A N=19 Randomized Double-blind Treatment

Serious Game-based Interventions in Patients With Mild Cognitive Impairment Outside the Clinic

Mild Cognitive Impairment

Bottom Line

View on ClinicalTrials.gov: NCT04920123 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2025

Primary outcome: Primary: Change in Montreal Cognitive Assessment (MoCA) — -2.0; 2.8 score on a scale — p=0.997

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Neuro-World (Device)
Age: Adult, Older Adult · 55+ yrs
Sex: All
Sponsor: University of Massachusetts, Amherst
Primary completion: Mar 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Montreal Cognitive Assessment (MoCA)	-2.0; 2.8	0.997
SECONDARY Change in Mini-Mental State Examination (MMSE)	0.5; 0.5	0.500
SECONDARY Change in Digit Forward Span (DFS)	-0.2; 0.8	0.821
SECONDARY Change in Digit Backward Span (DBS)	-1.1; 1.4	0.995
SECONDARY Change in Geriatric Depression Scale (GDS)	-0.8; 0.2	0.076
SECONDARY Change in Short Form 36 (SF-36) Mental Component Summary Score	-0.3; 0.3	0.432
SECONDARY Change in Lawton-Brody Instrumental Activities of Daily Living Scale (IADL)	-0.5; -0.1	0.750

Summary

This study will evaluate the therapeutic efficacy of Neuro-World cognitive training games (Woorisoft, S. Korea) in patients with mild cognitive impairment.

Eligibility Criteria

Inclusion Criteria

Seventeen points or greater and smaller than twenty-six points on the Montreal Cognitive Assessment (MoCA)
Fifty-five years old and above
Minimal technological literacy (i.e. ability to use a tablet independently)
Having a computer for online videoconferencing-based communication (necessary for online cognitive assessments)

Exclusion Criteria

Confounding neurological and psychiatric disorders
History of traumatic brain injury
Clinically known hearing or vision impairment
Severe upper-limb motor impairments that could impact the use of mobile devices
Clinical presentations suggestive of dementia with Lewy bodies, progressive supranuclear palsy, multiple system atrophy, or vascular parkinsonism
Diagnosis of dementia
Major depression
Any significant upper-limb impairment that could affect tablet use
Participation in any other therapist-supervised cognitive training

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04920123). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.